- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 94,03 | -0,50 % | Assembly Biosciences: ABI-4334 erreicht Studienziel - Gilead-Entscheidung steht bevor | Assembly Biosciences (WKN: A402CB) liefert weiter ab: Mit ABI-4334 fällt der erste wichtige Readout dieses Jahres positiv aus. Das HBV-Asset galt als das unsicherste im Portfolio. Die Aktie liebäugelt... ► Artikel lesen | |
| ZOETIS | 131,92 | -1,11 % | Minimales Kursplus bei der Zoetis-Aktie (142,2837 €) | Wenig Kursbewegung aktuell bei dem Anteilsschein von Zoetis . Das Papier kostete zuletzt 164,83 US-Dollar. Der Kurs der Aktie von Zoetis zeigt sich gegenwärtig kaum verändert im Vergleich zu der letzten... ► Artikel lesen | |
| INCYTE | 58,24 | -0,31 % | Leichte Zugewinne bei der Incyte-Aktie (60,38 €) | Im US-amerikanischen Wertpapierhandel liegt die Incyte-Aktie aktuell im Plus. Das Wertpapier notiert zur Stunde bei 60,38 Euro. Am US-amerikanischen Aktienmarkt hat sich heute die Incyte-Aktie zwischenzeitlich... ► Artikel lesen | |
| AMARIN | 13,100 | -0,76 % | Recordati: RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA IN EUROPE | RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
Vazkepa® supported by strong clinical data package and expected to contribute to Specialty... ► Artikel lesen | |
| CASSAVA SCIENCES | 1,585 | +4,48 % | Cassava Sciences reports simufilam reduced seizures in mouse model | ||
| LIGAND PHARMACEUTICALS | 97,50 | 0,00 % | ROUNDUP: Ligand Pharmaceuticals Reiterates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 1,794 | -6,07 % | Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades | Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 258,90 | +0,74 % | Madrigal, Viking among notable gainers after Altimmune's MASH setback | ||
| SEELOS THERAPEUTICS | 0,123 | -8,88 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| TALPHERA | 0,410 | +1,87 % | Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,080 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| RIGEL PHARMACEUTICALS | 16,100 | -3,01 % | Rigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business Update | First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 56,00 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin Gel for the Treatment of Acute Gout Flares | Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare... ► Artikel lesen | |
| SAVARA | 1,930 | +2,66 % | Savara Inc.: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences | Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase... ► Artikel lesen | |
| MOLECULAR TEMPLATES | 0,107 | -0,56 % | NSE - Molecular Templates, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
Das Unternehmen CORNERSTONE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.